Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Silvia Nozza

Showing results (141-150 of 175) with videos related to

Pageof 18
Sort By:
Plos One|October 13, 2021
Durability of Integrase STrand Inhibitor (InSTI)-based regimen in geriatric people living with HIV in the GEPPO cohortEmanuele Focà, Andrea Calcagno, Stefano Calza, et al.
British Journal of Clinical Pharmacology|September 17, 2022
Inflammation and intracellular exposure of dolutegravir, darunavir, tenofovir and emtricitabine in people living with HIVMicol Ferrara, Jessica Cusato, Elena Salvador, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|March 15, 2025
Effectiveness of dolutegravir-based vs boosted darunavir-based first-line 3-drug regimens in people with HIV with advanced disease: A trial emulationRoberta Gagliardini, Andrea Giacomelli, Cristina Mussini, et al.
AIDS (London, England)|February 26, 2021
Dolutegravir is not associated with weight gain in antiretroviral therapy experienced geriatric patients living with HIVGiovanni Guaraldi, Stefano Calza, Jovana Milic, et al.
Plos One|September 28, 2019
A prospective randomized trial on abacavir/lamivudine plus darunavir/ritonavir or raltegravir in HIV-positive drug-naïve patients with CD4<200 cells/uL (the PRADAR study)Cristina Mussini, Enrica Roncaglia, Vanni Borghi, et al.
Expert Review of Anti-Infective Therapy|October 15, 2020
Enhancing care for people living with HIV: current and future monitoring approachesFranco Maggiolo, Alessandra Bandera, Stefano Bonora, et al.
Open Forum Infectious Diseases|January 19, 2026
Bimonthly Administered Long-Acting Cabotegravir and Rilpivirine Are Highly Effective and Well-Tolerated in People With Human Immunodeficiency Virus Above 65 YearsAndrea Calcagno, Caterina Candela, Agostino Riva, et al.
AIDS Research and Therapy|October 8, 2008
The intracellular detection of MIP-1beta enhances the capacity to detect IFN-gamma mediated HIV-1-specific CD8 T-cell responses in a flow cytometric setting providing a sensitive alternative to the ELISPOTSarah Kutscher, Claudia J Dembek, Simone Allgayer, et al.
The Journal of Antimicrobial Chemotherapy|April 6, 2024
Long-term outcomes of bictegravir/emtricitabine/tenofovir alafenamide as first-line therapy and as switch strategy in virologically suppressed persons with HIV: data from the ICONA cohortAntonella d'Arminio Monforte, Alessandro Tavelli, Antonio Di Biagio, et al.
Kidney International Reports|April 24, 2026
Prospective Cohort Study of Felzartamab in Rituximab-Resistant Primary Membranous NephropathyMatias Trillini, Federica Casiraghi, Alessia Gennarini, et al.
Pageof 18

Showing results (141-150 of 175) with videos related to

Sort By:
Pageof 18
Plos One|October 13, 2021
Durability of Integrase STrand Inhibitor (InSTI)-based regimen in geriatric people living with HIV in the GEPPO cohortEmanuele Focà, Andrea Calcagno, Stefano Calza, et al.
British Journal of Clinical Pharmacology|September 17, 2022
Inflammation and intracellular exposure of dolutegravir, darunavir, tenofovir and emtricitabine in people living with HIVMicol Ferrara, Jessica Cusato, Elena Salvador, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|March 15, 2025
Effectiveness of dolutegravir-based vs boosted darunavir-based first-line 3-drug regimens in people with HIV with advanced disease: A trial emulationRoberta Gagliardini, Andrea Giacomelli, Cristina Mussini, et al.
AIDS (London, England)|February 26, 2021
Dolutegravir is not associated with weight gain in antiretroviral therapy experienced geriatric patients living with HIVGiovanni Guaraldi, Stefano Calza, Jovana Milic, et al.
Plos One|September 28, 2019
A prospective randomized trial on abacavir/lamivudine plus darunavir/ritonavir or raltegravir in HIV-positive drug-naïve patients with CD4<200 cells/uL (the PRADAR study)Cristina Mussini, Enrica Roncaglia, Vanni Borghi, et al.
Expert Review of Anti-Infective Therapy|October 15, 2020
Enhancing care for people living with HIV: current and future monitoring approachesFranco Maggiolo, Alessandra Bandera, Stefano Bonora, et al.
Open Forum Infectious Diseases|January 19, 2026
Bimonthly Administered Long-Acting Cabotegravir and Rilpivirine Are Highly Effective and Well-Tolerated in People With Human Immunodeficiency Virus Above 65 YearsAndrea Calcagno, Caterina Candela, Agostino Riva, et al.
AIDS Research and Therapy|October 8, 2008
The intracellular detection of MIP-1beta enhances the capacity to detect IFN-gamma mediated HIV-1-specific CD8 T-cell responses in a flow cytometric setting providing a sensitive alternative to the ELISPOTSarah Kutscher, Claudia J Dembek, Simone Allgayer, et al.
The Journal of Antimicrobial Chemotherapy|April 6, 2024
Long-term outcomes of bictegravir/emtricitabine/tenofovir alafenamide as first-line therapy and as switch strategy in virologically suppressed persons with HIV: data from the ICONA cohortAntonella d'Arminio Monforte, Alessandro Tavelli, Antonio Di Biagio, et al.
Kidney International Reports|April 24, 2026
Prospective Cohort Study of Felzartamab in Rituximab-Resistant Primary Membranous NephropathyMatias Trillini, Federica Casiraghi, Alessia Gennarini, et al.
Pageof 18